|
|
 |
|
Viewing report
|
|
|
|
U.S. Inflammatory Disease Drug Delivery - Patient Perspective
Frost & Sullivan, Nov 2010, Pages: 86
This study encompasses feedback provided by U.S. patients treated for inflammatory diseases on aspects of drug delivery and drug treatment, enabling interested stakeholders to gain insight on current and future trends. Analysis includes issues such as awareness, usage, preferences, influencing criteria, patient compliance, desired delivery types to be made available, as well as feedback on the role the device plays in the prescribing decision for a drug.
Market Overview
Oral Medication Gains Precedence over Other Options in the United States Among Patients with Inflammatory Diseases
Convenient and Easy to Self-administer, Oral Medication is Priced Lower than Other Drug Delivery Methods
Patients suffering from inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis have multiple drug delivery options to treat their condition including transdermal patches and topical gels/creams, injection, and intravenous infusion. While choosing a mode of treatment, patients mainly prefer a drug delivery method that offers them no or minimal discomfort. Another dominant consideration is ease of self-administration. While intravenous infusion is most associated with doctors’ preference, injection is most associated with the rapid onset of drug action. Transdermal patches and topical gel/cream are considered comfortable to use - the former is the second-most preferred type of drug delivery for Crohn’s disease and rheumatoid arthritis patients and the latter is the second-most preferred by psoriasis patients. Although each drug delivery method is associated with unique benefits such as minimal or no discomfort and rapid onset of drug action, the future of drug delivery for inflammatory diseases lies in the oral therapeutic market.
“Oral medication is significantly the most preferred method of drug delivery among patients with inflammatory diseases,” says the analyst of this research service. “It ranks the highest in ease of self-administration, convenience, and low-cost.” Of all drug delivery methods, patients are mostly aware of oral and injectable delivery types. Although about 99 percent of rheumatoid arthritis patients are aware of the oral form of medication, only 53 percent prefer using this method. In all, 75 percent of patients that use oral drug delivery for their psoriasis treatment are very satisfied/ satisfied against only 55 percent of topical gel/cream users being satisfied/ very satisfied. Sixty-six percent of Crohn’s disease patients and 91 percent of rheumatoid arthritis patients said they are very satisfied/ satisfied with oral delivery use in their treatment. Sixty percent of psoriasis patients use injection very frequently. Thirty-three percent rate pulmonary/ inhaled as being used very frequently.
“With the exception of psoriasis, a majority of patients take oral medication for their inflammatory condition,” observes the analyst. “There appears to be a significant opportunity for topical gel/cream due to psoriasis patients’ willingness to use it, in case it is available and affordable.” However, all patients feel that doctors do not prefer topical gel/cream for the treatment of psoriasis, which prevents them from using this delivery method. Most patients are satisfied with taking an oral drug instead of having an injection or using a topical gel/cream. About 60 percent patients reported ease of self-administration as the reason for their satisfaction with the method. Further, about 20 percent of the patients cited oral medication as convenient to use and 20 percent reported satisfaction due to its low cost.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Injection
- Transdermal
- Intranasal
- Oral
- Pulmonary
- Implant
- Ocular
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
2008 U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
2008 U.S. Chronic Pain Drug Delivery: Patient Perspective
2008 U.S. Diabetes Drug Delivery - Patient Perspective
U.S. Diabetes Drug Delivery - Physician Perspective
2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective
The Immunomodulators Market Outlook to 2016
U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
The Future of Autoimmune Diseases Therapeutics – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deal Analysis
Juvenile Idiopathic Arthritis - Disease-Subtype Heterogeneity Drives Diverse Treatment Options
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
|
|
|
|
